Reductil is a central-action anorectic drug, which has been widely used for the treatment of obesity and has been available in the pharmaceutical markets of many European countries about seven years ago.
Reductil is a trade name of the anti-obesity drug Sibutramine, which is now withdrawn from sale in most countries of the world. The reasons for the drug withdrawal were the results of a large-scale study, held in the US.
The results of the study have shown that Reductil significantly reduces body weight, but its use increases the risk of adverse consequences for the cardiovascular system.
Despite these studies, the drug is still available in some countries and is offered for sale by some online pharmacies.
Indications and contraindications
The drug is used for the treatment of alimentary obesity in adolescents of 16 years and older, and adults. Reductil is intended for the treatment of various degrees of obesity and overweight, which are determined in accordance with the body mass index (BMI).
Medication is prescribed to obese patients with a BMI of:
- 30 kg/m2 or higher;
- 27 to 29.9 kg/m2 and in the presence of such risk factors, as dyslipidaemia or diabetes mellitus type 2;
- Reductil should be used as maintenance therapy and in combination with diet and adequate physical activity for a maximum of 12 months.
Contraindications for Reductil use include:
- hypersensitivity to the ingredients of the drug;
- concurrent use with MAO inhibitors;
- eating disorders anorexia and bulimia nervosa;
- pregnancy and lactation;
- pediatric (under 16 years) and older (over 65) age.
The action mechanism of Reductil
The therapeutic effect of the drug is carried out, mainly in two ways:
Suppression of the reuptake of the neurotransmitters serotonin and norepinephrine in the synaptic cleft.
- Loss of appetite and hunger;
- Reduction in the amount of food consumed;
- Surge of energy and vivacity.
Mediated activation of β-adrenoceptors
- Increases thermogenesis and energy consumption;
- Stimulates lipolysis (breakdown of fat).
Reductil supports the energy expenditure rate and improves the carbohydrate metabolism. Use of anorectic drug Reductil improves lipid profile by reducing the level of:
- triglycerides and total cholesterol;
- low-density lipoproteins and uric acid.
Dosage form and dosing regimen of Reductil
The drug is produced in the form of oral capsules, which contain different amounts of the active substance Sibutramine. Each Reductil capsule may contain:
- 10 mg Sibutramine;
- 15 mg Sibutramine.
Reductil is taken once daily in the morning, regardless of the meal. Capsule should be swallowed whole and washed down with a full glass of water.
Initial dose of Reductil is 10 mg per day. As a rule, patients tolerate the drug well and lose weight successfully. However, the clinical response to the drug and the weight loss result may vary.
Therefore, during the first three months of therapy, people are recommended to measure the following at two-week intervals:
- Body Weight
- Blood Pressure
- Heart Rate
Provided good tolerability in case of inadequate weight loss, the daily dose is increased up to the maximum – 15 mg. Doses of the anorectic above 15 mg per day increase the risk of side effects.
If a patient was unable to lose weight by at least 5% of his original weight in three months of Reductil use, the drug is discontinued.
Reductil adverse effects
- The most common adverse events during the use of Reductil come from the part of the central nervous system: headache, insomnia, dizziness, feeling anxious.
- People can also mark hot flushes, nausea, palpitations, sweating, constipation, dry mouth. These side effects are usually not serious and pass as the therapy continues.
Such adverse reactions, as a sharp increase in blood pressure, blurred vision, convulsions, and fits require medical assistance. These effects are serious, yet develop quite rarely.
- When Reductil is combined with serotonergic agents, including the antidepressants, or with other anorectic drugs with a central mechanism of action, the risk of serotonin syndrome increases.
- Combination therapy with Reductil and Cyclosporine, Ketoconazole and macrolide antibiotics Troleandomycin and Erythromycin affect plasma concentrations of Sibutramine, which promotes a reduction in the effectiveness of treatment and appearance of unwanted effects.
- Avoid coadministration of Reductil with alcohol-containing beverages, since both exert a direct effect over the central nervous system and can simultaneously activate or block processes that occurr in it.